Quinolines and derivatives
Apexbio Technology LLC 17-AAG (KOS953) 75747-14-7 200mg
17-AAG (KOS953) is a synthetic derivative of geldanamycin that inhibits heat shock protein 90 (HSP90) It acts by binding to HSP90 causing destabilization of client proteins including HER2 Raf-1 p53 and components of MAPK signaling pathways Reported IC50 for 17-AAG in BT474 cells is approximately 6 nM Its biological activity has been investigated broadly including in multiple myeloma breast cancer thyroid cancer Hodgkin lymphoma and melanoma cellular models Ongoing studies explore 17-AAG both as monotherapy and in combination with agents like bortezomib or trastuzumab for addressing treatment-resistant cancer cell lines Currently 17-AAG is evaluated in Phase II clinical trials
Apexbio Technology LLC Oxaliplatin 61825-94-3 200mg
Oxaliplatin (CAS 61825-94-3) is a platinum-based chemotherapeutic agent that functions primarily by forming DNA adducts thereby disrupting DNA synthesis and ultimately inducing apoptosis via primary and secondary DNA damage It demonstrates antitumor activity against various cancer cell lines including melanoma (IC50 0 14 7 85 M) ovarian carcinoma (IC50 0 17 M) bladder cancer (IC50 11 15 M) colon cancer (IC50 2 95 M) and glioblastoma (IC50 17 6 30 9 M) Oxaliplatin is useful in preclinical animal tumor models and has clinical applications notably in metastatic colorectal cancer therapy combined with fluorouracil and folinic acid
Apexbio Technology LLC PCI-24781 (CRA-024781) 783355-60-2 200mg
PCI-24781 (CRA-024781 CAS 783355-60-2) is a histone deacetylase (HDAC) inhibitor targeting HDAC1 HDAC2 HDAC3 HDAC6 HDAC8 and HDAC10 with reported Ki values of 7 19 8 2 17 280 and 24 nM respectively HDAC enzymes catalyze the removal of acetyl groups from lysine residues on histone proteins thereby regulating chromatin structure and gene expression PCI-24781 induces dose-dependent hyperacetylation of histones and tubulin in human cancer cells (HCT116 DLD-1) leading to apoptosis via p21 upregulation PARP cleavage and H2AX accumulation PCI-24781 demonstrates antitumor activity against multiple tumor cell lines and in xenograft models highlighting its utility for oncology research